Allianz Asset Management GmbH Acquires New Position in AnaptysBio, Inc. $ANAB

Allianz Asset Management GmbH acquired a new stake in shares of AnaptysBio, Inc. (NASDAQ:ANAB) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 15,200 shares of the biotechnology company’s stock, valued at approximately $337,000. Allianz Asset Management GmbH owned 0.05% of AnaptysBio as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Moody Aldrich Partners LLC purchased a new position in shares of AnaptysBio during the first quarter valued at approximately $1,547,000. BIT Capital GmbH purchased a new position in shares of AnaptysBio during the first quarter valued at approximately $473,000. HighMark Wealth Management LLC raised its stake in AnaptysBio by 58.2% during the second quarter. HighMark Wealth Management LLC now owns 145,550 shares of the biotechnology company’s stock worth $3,231,000 after purchasing an additional 53,550 shares during the period. Nuveen LLC purchased a new position in AnaptysBio during the first quarter worth approximately $1,041,000. Finally, First Light Asset Management LLC raised its stake in AnaptysBio by 433.3% during the first quarter. First Light Asset Management LLC now owns 4,633,602 shares of the biotechnology company’s stock worth $86,139,000 after purchasing an additional 3,764,720 shares during the period.

AnaptysBio Price Performance

NASDAQ ANAB opened at $36.16 on Wednesday. AnaptysBio, Inc. has a 12 month low of $12.21 and a 12 month high of $37.00. The company has a market capitalization of $1.01 billion, a price-to-earnings ratio of -8.07 and a beta of -0.18. The company’s fifty day moving average price is $26.17 and its two-hundred day moving average price is $23.73.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings data on Wednesday, August 6th. The biotechnology company reported ($1.34) EPS for the quarter, beating analysts’ consensus estimates of ($1.50) by $0.16. AnaptysBio had a negative net margin of 107.66% and a negative return on equity of 366.98%. The firm had revenue of $22.26 million for the quarter, compared to the consensus estimate of $11.55 million. As a group, analysts anticipate that AnaptysBio, Inc. will post -6.08 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on ANAB shares. Wedbush increased their price target on shares of AnaptysBio from $45.00 to $70.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 15th. UBS Group reaffirmed a “neutral” rating and set a $20.00 price target (up previously from $18.00) on shares of AnaptysBio in a research note on Tuesday, August 12th. JPMorgan Chase & Co. increased their price objective on shares of AnaptysBio from $42.00 to $80.00 and gave the stock an “overweight” rating in a research report on Thursday, July 24th. Weiss Ratings reissued a “sell (d-)” rating on shares of AnaptysBio in a research report on Wednesday, October 8th. Finally, HC Wainwright increased their price objective on shares of AnaptysBio from $38.00 to $59.00 and gave the stock a “buy” rating in a research report on Tuesday, September 30th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, AnaptysBio presently has a consensus rating of “Moderate Buy” and a consensus price target of $54.78.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.